BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34358157)

  • 1. Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection.
    Del Rosario JMM; da Costa KAS; Asbach B; Ferrara F; Ferrari M; Wells DA; Mann GS; Ameh VO; Sabeta CT; Banyard AC; Kinsley R; Scott SD; Wagner R; Heeney JL; Carnell GW; Temperton NJ
    Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudotyped Viruses for Influenza.
    Del Rosario JMM; da Costa KAS; Temperton NJ
    Adv Exp Med Biol; 2023; 1407():153-173. PubMed ID: 36920696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays.
    Wang W; Xie H; Ye Z; Vassell R; Weiss CD
    J Virol Methods; 2010 May; 165(2):305-10. PubMed ID: 20153374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudotype-based neutralization assays for influenza: a systematic analysis.
    Carnell GW; Ferrara F; Grehan K; Thompson CP; Temperton NJ
    Front Immunol; 2015; 6():161. PubMed ID: 25972865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza.
    Andersen TK; Zhou F; Cox R; Bogen B; Grødeland G
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design.
    da Costa KAS; Del Rosario JMM; Ferrari M; Vishwanath S; Asbach B; Kinsley R; Wagner R; Heeney JL; Carnell GW; Temperton NJ
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies.
    Wang W; Butler EN; Veguilla V; Vassell R; Thomas JT; Moos M; Ye Z; Hancock K; Weiss CD
    J Virol Methods; 2008 Nov; 153(2):111-9. PubMed ID: 18722473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-Protection by Inactivated H5 Prepandemic Vaccine Seed Strains against Diverse Goose/Guangdong Lineage H5N1 Highly Pathogenic Avian Influenza Viruses.
    Criado MF; Sá E Silva M; Lee DH; Salge CAL; Spackman E; Donis R; Wan XF; Swayne DE
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies.
    Nakajima R; Supnet M; Jasinskas A; Jain A; Taghavian O; Obiero J; Milton DK; Chen WH; Grantham M; Webby R; Krammer F; Carter D; Felgner PL; Davies DH
    mSphere; 2018 Dec; 3(6):. PubMed ID: 30541779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Pan-H1 Influenza Vaccine.
    Darricarrère N; Pougatcheva S; Duan X; Rudicell RS; Chou TH; DiNapoli J; Ross TM; Alefantis T; Vogel TU; Kleanthous H; Wei CJ; Nabel GJ
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
    Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
    Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computationally Optimized Broadly Reactive H2 HA Influenza Vaccines Elicited Broadly Cross-Reactive Antibodies and Protected Mice from Viral Challenges.
    Reneer ZB; Jamieson PJ; Skarlupka AL; Huang Y; Ross TM
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterosubtypic antibodies to influenza A virus have limited activity against cell-bound virus but are not impaired by strain-specific serum antibodies.
    Wyrzucki A; Bianchi M; Kohler I; Steck M; Hangartner L
    J Virol; 2015 Mar; 89(6):3136-44. PubMed ID: 25552718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes.
    Ferrara F; Molesti E; Böttcher-Friebertshäuser E; Cattoli G; Corti D; Scott SD; Temperton NJ
    J Mol Genet Med; 2012; 7():309-14. PubMed ID: 23577043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.